The combination of anticholinergics and antagonists of leukotriene receptors for the treatment of respiratory diseases and a pharmaceutical composition based on it

摘要

1. The combination of an anticholinergic that is selected from the group consisting of racemic glycopyrrolate, one of its enantiomers, especially R, R-glycopyrrolate, one of its diasteremers and their physiologically acceptable salts and mixtures, and at least one leukotriene inhibitor for the treatment of respiratory diseases, selected from the group comprising allergic rhinitis, bronchial asthma, chronic obstructive pulmonary disease, and a common cold. ! 2. The combination according to claim 1, in which the anticholinergic is R, R-glycopyrrolate or its physiologically acceptable salts. ! 3. The combination according to claim 1, in which the leukotriene inhibitor is selected from the group comprising montelukast, zafirlukast, pranlukast, L-648,051, MK-571, verlukast (MK-0679), pobilukast (8K & F 104353-Z2), AS-35, ICI 204,219, telukast (LY 171,883) or their physiologically acceptable salts. ! 4. The combination according to claim 1, in which the daily dose of the leukotriene inhibitor is from 1 to 100 mg, preferably from 5 to 20 mg. ! 5. The combination according to claim 1, in which the daily dose of R, R-glycopyrrolate is from 1 to 500 μg. ! 6. The combination according to claim 5, in which the daily dose of R, R-glycopyrrolate is from 5 to 100 μg. ! 7. A pharmaceutical composition for treating respiratory diseases such as allergic rhinitis, bronchial asthma, chronic obstructive pulmonary disease or a common cold containing an anticholinergic selected from the group consisting of racemic glycopyrrolate, one of its enantiomers, especially R, R-glycopyrrolate and one of its diasteremers and their physiologically acceptable salts or mixtures thereof, and at least one leukotriene inhibitor. ! 8. The pharmaceutical composition according to claim 7, which